Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease with unknown cause. It mainly affects joints and, without proper treatment, negatively impacts their movement, causes painful deformities, and reduces the patients' quality of life. Current treatment options consist of various types of disease-modifying antirheumatic drugs (DMARDs), however 20-30% of patients are partially resistant to them. Therefore, development of new drugs is necessary. Possible option are compounds exhibiting their action via endocannabinoid system, which plays an important role in pain and inflammation modulation. One such compound - cannabidiol (CBD) has already been shown to attenuate synovitis in animal model of RA in in vivo studies. However, it has low bioavailability due to its low water solubility and lipophilicity. This issue can be addressed by preparation of a lipid containing formulation targeting lymphatic system, another route of absorption in the body. Materials and Methods: CBD-containing emulsion was prepared by high-shear homogenization and its droplet size distribution was analysed by optical microscopy. The relative oral bioavailability compared to oil solution as well as total availability of CBD were assessed in a cross-over study in rats and absorption of CBD via lymphatic system was observed. The effect of CBD on the animal model of RA was determined. Results: Compared to oil solution, the emulsion exhibited higher absolute oral bioavailability. Significant lymphatic transport of CBD was observed in all formulations and the concentrations in lymph were calculated. The therapeutic effect of CBD on RA was confirmed as an improvement in clinical symptoms as well as morphological signs of disease activity were observed during the study. Conclusion: In this work, we prepared a simple stable emulsion formulation, determined the pharmacokinetic parameters of CBD and calculated its absolute bioavailability in rats. Moreover, we successfully tested the pharmaceutical application of such a formulation and demonstrated the positive effect of CBD in an animal model of RA.

3rd Department of Surgery 1st Faculty of Medicine Charles University Prague and Motol University Hospital Prague Czech Republic

Department of Analytical Chemistry Faculty of Science Charles University Prague Czech Republic

Department of Chemical Engineering Faculty of Chemical Engineering University of Chemistry and Technology Prague Czech Republic

Institute of Histology and Embryology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9:249–262. PubMed PMC

Kerschbaumer A, Sepriano A, Smolen JS, et al. . Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:744–759. PubMed PMC

Kaur I, Behl T, Bungau S, et al. . The endocannabinoid signaling pathway as an emerging target in pharmacotherapy, earmarking mitigation of destructive events in rheumatoid arthritis. Life Sci. 2020;257:118109. PubMed

Malfait AM, Gallily R, Sumariwalla PF, et al. . The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97:9561–9566. PubMed PMC

Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977;146:857–868. PubMed PMC

EMA. Epidyolex; [cited 2022 May 1]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex

Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–248. PubMed

Charman WNA, Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34:175–178.

Ryšánek P, Grus T, Šíma M, et al. . Lymphatic transport of drugs after intestinal absorption: impact of drug formulation and physicochemical properties. Pharm Res. 2020;37:166. PubMed

Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770–1804. PubMed PMC

Zgair A, Lee JB, Wong JCM, et al. . Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Sci Rep. 2017;7:14542. PubMed PMC

Franco V, Gershkovich P, Perucca E, et al. . The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations. Clin Pharmacokinet. 2020;59:1493–1500. PubMed

Lowin T, Tingting R, Zurmahr J, et al. . Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11:714. PubMed PMC

Millar SA, Stone NL, Yates AS, et al. . A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365. PubMed PMC

Francke NM, Schneider F, Baumann K, et al. . Formulation of cannabidiol in colloidal lipid carriers. Molecules. 2021;26:1469. PubMed PMC

Izgelov D, Shmoeli E, Domb AJ, et al. . The effect of medium chain and long chain triglycerides incorporated in self-nano emulsifying drug delivery systems on oral absorption of cannabinoids in rats. Int J Pharm. 2020;580:119201. PubMed

Trevaskis NL, Hu L, Caliph SM, et al. . The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport. J Vis Exp. 2015:52389. PubMed PMC

EMA. ICH guideline M10 on bioanalytical method validation and study sample analysis; [cited 2022 May 1]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf

Ryšánek P, Grus T, Lukáč P, et al. . Validity of cycloheximide chylomicron flow blocking method for the evaluation of lymphatic transport of drugs. Br J Pharmacol. 2021;178:4663–4674. PubMed

Deiana S, Watanabe A, Yamasaki Y, et al. . Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219:859–873. PubMed

Feng W, Qin C, Chu Y, et al. . Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. Eur J Pharm Biopharm. 2021;162:43–49. PubMed

Hložek T, Uttl L, Kadeřábek L, et al. . Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol. 2017;27:1223–1237. PubMed

Kok LY, Bannigan P, Sanaee F, et al. . Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol. Eur J Pharm Sci. 2022;168:106058. PubMed

Stella B, Baratta F, Della Pepa C, et al. . Cannabinoid formulations and delivery systems: current and future options to treat pain. Drugs. 2021;81:1513–1557. PubMed PMC

Dahan A, Hoffman A. Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci. 2005;24:381–388. PubMed

Karpf DM, Holm R, Kristensen HG, et al. . Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats. Pharm Res. 2004;21:1413–1418. PubMed

Trevaskis NL, Lee G, Escott A, et al. . Intestinal lymph flow, and lipid and drug transport scale allometrically from pre-clinical species to humans. Front Physiol. 2020;11:458. PubMed PMC

Perucca E, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. CNS Drugs. 2020;34:795–800. PubMed

El-Sheikh SMA, Abd El-Alim AEF, Galal AAA, et al. . Anti-arthritic effect of β-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats. Life Sci. 2019;233:116750. PubMed

Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats